Mesterolone (Proviron)

The 1α-methyl group makes it orally active without the heavy liver toxicity of 17α-alkylated steroids, and because it is already 5α-reduced (a DHT analog) it is NON-AROMATIZABLE — it cannot be converted to estradiol.

Pharmacologically it is an unusual androgen: in receptor-binding studies it binds the androgen receptor in muscle and prostate relatively weakly (a weak anabolic), yet binds sex-hormone-binding globulin (SHBG) extremely avidly — about four times more strongly than DHT itself.

That SHBG affinity is the mechanistic basis for its main off-label rationale in the bodybuilding community: by occupying SHBG it can transiently raise the free (unbound) fraction of a person's own or co-administered testosterone, and its DHT-like signaling is credited anecdotally with libido and a 'hardening'/anti-estrogenic feel.

None of those bodybuilding uses are well evidenced in controlled trials. Mesterolone's licensed indications are male hypogonadism/androgen deficiency and, historically, idiopathic male infertility — and the infertility evidence is where the honest picture turns negative.

The premise was that a 'stimulatory' androgen given at a dose low enough not to suppress pituitary gonadotrophins might directly support spermatogenesis or sperm maturation in the epididymis. That premise largely failed in controlled testing.

A large WHO Task Force multicentre randomized double-blind trial of 75 or 150 mg/day mesterolone vs placebo in idiopathic male infertility found no significant difference in pregnancy rate or semen quality.

A Belgian double-blind placebo-controlled trial of high-dose (150 mg/day) mesterolone for 12 months actually saw a higher pregnancy rate in the placebo arm, with the authors concluding the data 'cast doubt' on its usefulness.

A randomized comparison against clomiphene found mesterolone (like placebo) did not significantly raise sperm concentration or pregnancies, while clomiphene did.

The Cochrane systematic review of androgens (including mesterolone) for idiopathic oligo/asthenospermia concluded there is not enough evidence to support their use, with pooled pregnancy odds ratios crossing 1.0. So the marketed fertility indication is, on the controlled evidence, weak-to-absent.

Some smaller and older studies report softer benefits — improved subjective potency/'aging male' symptom scores and lower-urinary-tract quality of life, and the predictable endocrine signature of an exogenous androgen (suppressed total testosterone, estradiol, and SHBG, with a rise in the free-testosterone fraction).

The safety side is the side of a real androgen: as a 5α-reduced DHT derivative it can drive androgenic effects (acne, oily skin, accelerated male-pattern hair loss, prostate stimulation), it can adversely shift lipids (lower HDL) like other oral AAS, in-vitro work groups it with anabolic steroids that disturb adrenal steroidogenesis (a proposed mineralocorticoid/cardiovascular concern), and at higher doses any androgen can suppress the hypothalamic-pituitary-testicular axis.

It is a prescription anabolic-androgenic steroid and a doping agent on the WADA list — not a dietary supplement, not a longevity drug.

The overall picture: a genuine, mechanistically-distinct androgen (non-aromatizable, SHBG-binding, weakly anabolic) whose headline marketed use — improving male fertility — is not supported by controlled trials, whose bodybuilding uses are poorly evidenced, and which carries the androgenic risks of its class.

This is a hormonal compound for harm-reduction information, not a recommendation.